In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the ...

Says therapeutic portfolio ‘demonstrating very strong momentum’ into 2025. Says making “significant progress” in R&D efforts. Invest with ...

AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...